You are here

VRTX

$117.42

+0.93%

Investor Relations

News & Events

Filter Releases
 
Press Releases
Date Title and Summary View
Jan 8, 2017
-Full-year 2016 product revenues of approximately $703 million for KALYDECO and $979 million for ORKAMBI; total 2016 CF product revenues of $1.68 billion compared to $983 million in 2015- -Company provides 2017 financial guidance for KALYDECO product revenues of $690 to $710 million and ORKAMBI pr...
Jan 10, 2016
-Approximately 25,000 people with cystic fibrosis worldwide currently eligible for treatment with ORKAMBI® (lumacaftor/ivacaftor) or KALYDECO® (ivacaftor); Vertex advancing the development of multiple medicines with the goal of treating all people with cystic fibrosis- -Fourth q...
Nov 23, 2015
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Michael J. Parini to the role of Executive Vice President and Chief Legal Officer. Mr. Parini will serve as a member of Vertex's Executive Committee, reporting directly to Jeffrey Leiden, M.D.,...
Aug 19, 2015
Hosts August 19th back to school event with Bottom Line for 200+ first-generation college students BOSTON--(BUSINESS WIRE)-- Vertex and the University of Massachusetts (UMass) today announced the recipients of the annual Vertex Science Leaders Scholarship, a four-y...
Jun 18, 2015
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Sangeeta N. Bhatia, M.D., Ph.D., joined its board of directors as an independent director. Dr. Bhatia was elected to serve a three-year term ending in 2018. "Dr. Bhatia is a leading ...
Jan 11, 2015
-Priority Review granted for combination of lumacaftor and ivacaftor in people with cystic fibrosis ages 12 and older who have two copies of the F508del mutation; PDUFA date of July 5, 2015- -More than 3,700 people with CF expected to be eligible to receive KALYDECO by end of 2015 supporting conti...
Dec 15, 2014
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated today announced that David Altshuler, M.D., Ph.D., will join the company as Executive Vice President, Global Research and Chief Scientific Officer. Dr. Altshuler was one of the four founding members of the Broad Institute of Harvard University...
Jul 10, 2014
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Peter Mueller, Ph.D., Executive Vice President of Global Research and Development and Chief Scientific Officer, will retire after more than 10 years with the company. Dr. Mueller's retirement will be effecti...
May 7, 2014
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that William Young joined its board of directors as an independent director. Mr. Young was elected to the class of directors whose term expires in 2017. The Vertex board now consists of 10 members. ...
Jan 12, 2014
-KALYDECO: 2014 revenue growth anticipated from geographic expansion and approval for use in patients with additional CFTR mutations- -Lumacaftor in combination with ivacaftor: results from two Phase 3 studies, TRAFFIC and TRANSPORT, expected mid-year in people with two copies of the F508...
Jan 8, 2014
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Jeffrey A. Chodakewitz, M.D., as Chief Medical Officer and Senior Vice President. Dr. Chodakewitz has more than 20 years of experience leading global development organizations in the b...
Jun 18, 2013
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has completed its previously announced call for redemption of $400 million in aggregate principal amount of 3.35% Convertible Senior Subordinated Notes due 2015. Holders of $400 million in aggre...
May 17, 2013
-2015 Notes convertible at a conversion price of approximately $48.83 per share- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that it has called for redemption of its outstanding $400.0 million in aggregate principal amoun...
Apr 5, 2013
-Two Phase 2 studies to evaluate once-daily combination of Vertex's investigational nucleotide analogue VX-135 and BMS' investigational NS5A replication complex inhibitor daclatasvir- -Study in people with genotype 1 hepatitis C planned to begin in second quarter of 2013- ...
Jan 6, 2013
-2013 investment focused on key development programs in cystic fibrosis, hepatitis C and autoimmune diseases- -First two Breakthrough Therapy Designations from U.S. FDA granted to ivacaftor monotherapy and to the combination regimen of VX-809 and ivacaftor for the treatment of cystic fibrosis- ...